ArticleAnnals of nuclear medicine2020
Preclinical PET imaging study of lung cancer with
Article in Annals of nuclear medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Application of artificial intelligence in lung cancer diagnosis, therapy, and prognosis.BMC medical genomics · 2026Review
- Preclinical Theranostic Profiling of [Molecules (Basel, Switzerland) · 2025Article
- Recent Advances in Preclinical Studies of the Theranostic Agent [Molecules (Basel, Switzerland) · 2024Review
- Improvement of Crystal Identification Accuracy for Depth-of-Interaction Detector System with Peak-to-Charge Discrimination Method.Sensors (Basel, Switzerland) · 2023Article
- Editorial:Frontiers in medicine · 2023Article
- Recent Advances in Cancer Imaging withNuclear medicine and molecular imaging · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveHuman copper transporter 1 (CTR1) has been proven to be overexpressed in many types of cancer cells, and copper (II)-64 chloride (
methodsThe expression of CTR1 in a series of lung cancer cell lines was identified by quantitative real-time polymerase chain reaction (Q-PCR), western blot, enzyme-linked immunosorbnent assay (ELISA), and immunofluorescent staining. Then in vitro cell uptake assay of
resultsThe CTR1 expression in multiple human lung cancer cells was identified and confirmed, and H1299 cell lines with high CTR1 expression, H460 with moderate CTR1, and H1703 with low CTR1 were selected for further experiments. In vitro cellular uptake assay displayed that the
conclusionsThe expression of CTR1 in human lung cancer xenograft model could be successfully visualized by
Indexed as
Identifiers
32567008What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.